FATE · Fate Therapeutics, Inc.

Fate Therapeutics reported first quarter 2026 financial results, highlighting a 20% reduction in operating expenses compared to the prior year quarter, which helped extend the company's cash runway into 2028. Revenue of $1.3 million was derived from preclinical development activities under the Ono Pharmaceutical collaboration. Total operating expenses were $34.3 million, with R&D expenses of $24.7 million and G&A expenses of $9.6 million, including $3.9 million in non-cash stock-based compensation. The company ended the quarter with $174.8 million in cash, cash equivalents, and investments.

Key clinical developments include the planned initiation of RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 in lupus nephritis, in the second half of 2026. FT819 was also selected for the FDA's CDRP program, which provides enhanced CMC regulatory engagement. The company presented positive Phase 1 data for FT819 at multiple medical conferences, showing durable responses and a favorable safety profile. Additionally, FT839, a next-generation dual-CAR T-cell product, is expected to enter Phase 1 trials in autoimmune diseases in H2 2026, and FT836 continues enrollment in a Phase 1 solid tumor study. Management expressed confidence in 2026 as a defining year, supported by regulatory milestones and a strong cash position.